Worldwide Business with kathy ireland® Streaming LIVE Sun. 4/26 and Weds. 4/29

Worldwide Business with kathy ireland® is excited to announce that they will be LIVE streaming this week’s episode of their successful business program on Sunday, April 26, 2020 and Wednesday, April 29, 2020 at 8:00pm ET / PT

LOS ANGELES (PRWEB)
April 23, 2020

Worldwide Business with kathy ireland® is excited to announce that they will be LIVE streaming this week’s episode of their successful business program on Sunday, April 26, 2020 and Wednesday, April 29, 2020 at 8:00pm ET / PT for ease of viewing and sharing! This episode’s exclusive interviews will spotlight key executives from Blue Eagle Consulting, FLUIDDA, AnswerConnect, and Regent University.

As leaders in their industries, the four companies featured demonstrate the unique branding opportunity Worldwide Business with kathy ireland® offers by bringing strategic messages and unique solutions to the business community.

Company Spotlight

Blue Eagle Consulting: Headquartered in Birmingham, Alabama, and with a network of seasoned information systems professionals, Blue Eagle Consulting provides healthcare organizations with the people they need to ensure their large software investments perform as expected. Blue Eagle Consulting consultants are those in the top ten percent in their field, with 10 to 20 years in the field and/or five to seven years of qualified experience.

President, Mark Griffin states that Blue Eagle Consulting stands out from other consulting services for many reasons; one of which is their quick turnarounds. He explains, “We have the proven ability to deliver. On average, it only takes us about seven to ten business days from the time we have a conversation with a client until we’ve paired a consultant or group of consultants for the needs they have.”

FLUIDDA: Headquartered in Belgium, FLUIDDA is leading the field of functional respiratory imaging (FRI) with their company’s technique which combines HRCT scans and computational fluid dynamics technology. In a world where the quality of air is under stress, and with one person dying from a respiratory condition every minute, patients with pulmonary diseases deserve better, faster, less costly treatments. FLUIDDA’s mission is to optimize treatment pathways, reduce healthcare costs and limit the go-to-market time of respiratory drugs, pulmonology medical devices and therapies.

CEO, Dr. Jan DeBacker says that they are actually able to help people with COVID-19. He explains, “This virus binds in the lungs to the receptors. The body tries to fight the virus by creating an inflammatory response… In the early stages, FLUIDDA can detect how much the lungs are already compensating for this disease and predict whether a patient will stay stable or if the patient is at risk of ending up in the ICU.”

AnswerConnect: Headquartered in Portland, Oregon, and serving clients around the world since 1994, AnswerConnect delivers exceptional customer care and has continuously adapted to the changing landscape of business and communication. From 24/7 answering services to industry-specific contact center solutions, the company’s ever-increasing portfolio of service offerings for early start-ups to multinational organizations has helped them grow consistently year after year.

CEO, Natalie Ruiz explains that AnswerConnect provides unique tools and services for virtual workers – a need that many companies are newly experiencing right now. She states, “At our core, we provide virtual reception and answering services, making sure that phone calls are answered 24/7/365 for our businesses… they can stay connected to their teams, whether they’re out in the field, at their office, or at their home office.”

Regent University: Founded in 1978, Regent University’s 11,000 students study on either its 70-acre campus in Virginia Beach, VA., or online around the world. The university offers associate’s, bachelor’s, master’s and doctoral degrees from a Christian perspective in more than 135 program areas. To encourage social distancing and to help ease financial struggles associated with COVID-19, Regent University is now offering a “social distancing scholarship” to all new students who are pursuing their bachelor’s, master’s or doctoral degree online with Regent.

Vice President of Academic Affairs, Dr. Gerson Moreno-Riano shares that Regent University always strives to serve its students, and that COVID-19 and the uncertainty surrounding the virus will not slow that down. He says, “Our social distancing scholarship gives students the opportunity to begin their program here at Regent to prepare for the future economy and future market.”

To learn more about the companies above, click here on Sunday, April 26, 2020 and Wednesday, April 29, 2020 at 8:00pm ET / PT to watch the LIVE stream of this week’s episode of Worldwide Business with kathy ireland®!

About Worldwide Business with kathy ireland®

Worldwide Business with kathy ireland® is a weekly half-hour show featuring global executives sharing their business insights and framing the opportunities shaping their industries. Hosted by a business mogul, Kathy Ireland interviews some of the brightest minds in business today. The show broadcasts on Fox Business Network as part of their sponsored content line up and globally on Bloomberg Television. Worldwide Business with kathy ireland® extends beyond the weekly on-air program with digital content delivered on various video platforms and across social media.

Share article on social media or email:

We are thrilled with the success of Tuesday night’s launch event with the cast of ‘Roswell, New Mexico.’ We could not have picked a better cast to join us in supporting Feeding America. We’re already hard at work planning future Cast4Good online chats to benefit other worthy causes.

NEW YORK (PRWEB)
April 23, 2020

Cast4Good was founded by Todd Krim, President & CEO of The Krim Group, as a creative new fundraising initiative in response to the ongoing global COVID-19 crisis, but will soon be expanded to support a wide range of charities and causes including climate change, humanitarian relief, social justice reform and gender equality. With the advent of social distancing and so many individuals turning towards entertainment for comfort and solace, Cast4Good unites cast members from beloved television series and films for exclusive one-hour moderated discussions and fan Q&As that audiences globally can watch and participate in from the comfort of their own homes – all while raising funds for charity and fostering a sense of community during these unprecedented times. Proceeds raised from the ticket sales are donated to the charity organization being highlighted.

The debut Cast4Good event took place on Tuesday, April 21st with the cast of The CW’s “Roswell, New Mexico,” as well as the creator and producer Carina Adly MacKenzie. Immediately following the panel, fans had the opportunity to have 1-on-1 video chats with select cast members via the digital platform, Looped. Proceeds raised from this inaugural event are being donated to Feeding America® and their COVID-19 Response Fund, a national food-and-fundraising effort to support people facing hunger and local food banks who help them.

“We are so thrilled with the success of last night’s launch event with the cast of ‘Roswell, New Mexico.’ We could not have picked a better cast to join us in our ‘give back’ efforts and the fan engagement was through the roof. We’re already hard at work planning future ‘cast chats’ to benefit other worthy causes,” said Cast4Good founder Todd Krim.

For media distribution, please find the following link to access a highlight reel from the launch event.

For more information on Cast4Good and to join the online community, please visit http://www.Cast4Good.com.

ABOUT TODD KRIM AND THE KRIM GROUP:

A lawyer-turned-charity matchmaker, Todd Krim, left his successful law practice to pursue a higher calling. Over the past decade Todd, known in Hollywood circles as “Mr. Charity,” has become the entertainment industry’s go-to person for charities looking to connect with celebrities and vice versa. He’s fostered partnerships between countless nonprofits and celebrities, advised for-profit companies on social impact campaigns, and produced widely publicized charity events including Richard Branson’s Venezuela Aid Live benefit in Colombia and the United Nations’ “Play It Out” Music Festival in Antigua. He has been featured in major magazines and media outlets including Variety, The Hollywood Reporter, USA Today, The New York Times, The Chronicle of Philanthropy, Real Leaders Magazine and Global Citizen Magazine. His most recent project, the “World Is In Our Hands” social media campaign he launched with director/photographer Justin Wu, supports the UN Environment Programme’s ActNow campaign and features Antonio Banderas, Joaquin Phoenix, Susan Sarandon, Rainn Wilson, Evan Peters, Maggie Q and Rosario Dawson, to name a few. Visit http://www.TheKrimGroup.com.

ABOUT FEEDING AMERICA®:

Feeding America® is the largest hunger-relief organization in the United States. Through a network of 200 food banks and 60,000 food pantries and meal programs, we provide meals to more than 40 million people each year. Feeding America also supports programs that prevent food waste and improve food security among the people we serve; educates the public about the problem of hunger; and advocates for legislation that protects people from going hungry. Individuals, charities, businesses and government all have a role in ending hunger. Donate. Volunteer. Advocate. Educate. Together we can solve hunger. Visit http://www.FeedingAmerica.org.

ABOUT LOOPED:

Looped is a platform where fans connect virtually with their favorite talent – anytime and anywhere in the world. Talent can go live for their fans, and even upgrade fans to VIP for access to a virtual meet & greet. Visit http://www.LoopedLive.com.

ABOUT ROSWELL, NEW MEXICO:

Roswell, New Mexico is from Warner Bros. Television and CBS Television Studios, in association with Amblin Television and Bender Brown Productions, with executive producers Carina Adly MacKenzie (The Originals), Christopher Hollier (Once Upon a Time), Julie Plec (The Vampire Diaries), Darryl Frank and Justin Falvey (The Americans), Lawrence Bender (Pulp Fiction) and Kevin Kelly Brown (Roswell). Roswell, New Mexico airs on The CW on Mondays at 9:00PM.

CAST4GOOD:

Website: http://www.Cast4Good.com

Instagram: @Cast4Good

Twitter: @Cast4Good

Facebook: @Cast4Good

Official Hashtag: #Cast4Good

MEDIA CONTACTS:

Jessica Sze

Shelter PR

E-mail: JessicaS@shelterpr.com

Molly Stead

Shelter PR

E-mail: MollyS@shelterpr.com

Share article on social media or email:

“The Local Risk Index highlights hot spots where the virus is accelerating in a dramatic way.”

INDIANAPOLIS (PRWEB)
April 23, 2020

Today, hc1 announced a powerful Local Risk Index (LRI) now available within cv19dashboard.org that delivers at-a-glance analysis of accelerating or decelerating COVID-19 infection rates by county and Public Use Microdata Area (PUMA).

“Healthcare planners will be alerted to where and when action must occur,” said Peter Plantes, M.D., hc1 Physician Executive. “Based on the known average clinical course of COVID-19 (from incubation to potential ICU-transfer and ventilation), timely, local data visualization enables users to predict 5 to 21 days in advance an acceleration of patient volumes with symptomatic COVID-19, and the associated increase in local demand for COVID-19 care resources like ER visits, hospitalizations, and ICU transfers.”

A clinical advisory team of epidemiological and healthcare experts advised hc1 in developing the LRI. “The Local Risk Index highlights hot spots where the virus is accelerating in a dramatic way. And if the LRI is falling then the virus spread is decelerating within the selected population area. Public health officials and hospitals can respond accordingly to these realtime objective measurements from the community,” said Richard Olds, MD, MCAP, International Expert – Infectious Diseases, Former U.S. Medical School Dean. “Think of it like a pollen count. If your local county has a high pollen score, then you’re more likely to develop active allergy symptoms.”

Anonymized trending data from a coalition of more than 20,000 lab testing locations supports the COVID-19 Lab Testing Dashboard’s Local Risk Index, as well as visualizations of COVID-19 testing rates, positive and negative test results, and key demographic filters like age and gender down to the county and sub-county (Public Use Microdata Area) level. Approximately 40 percent of the national COVID-19 lab testing results are reflected in the dashboard’s insights.

“Partners across the country have told us health systems and public health officials need more timely and granular insight to better plan for and address the needs of the CV-19 pandemic,” said Brad Bostic, hc1 CEO. “hc1’s core business focuses on transforming lab data into personalized healthcare insights. Given our unique assets and capabilities, we mobilized our team and lab coalition partners to quickly deliver a critical component of national surveillance infrastructure that addresses these challenges.”

The CV19 Lab Testing Dashboard powered by hc1 is a free public health service for individuals directly involved with implementing policies and delivering care to mitigate the spread of COVID-19. Included are public health officials, government agencies, and healthcare providers. Qualified individuals need only request access at cv19dashboard.org.

All trends in the dashboard are based on de-identified, aggregated data in accordance with the Health Insurance Portability and Accountability Act (HIPAA) privacy requirements. Accredited COVID-19 testing labs are encouraged to learn more and support this important public health initiative by visiting cv19dashboard.org/join.html.

About hc1®

Founded to improve lives with high-value care, hc1 has emerged as the leader in bioinformatics for precision testing and prescribing. The cloud-based hc1 High-Value Care Platform® organizes volumes of live data, including lab results, genomics, and medications, to deliver solutions that ensure that the right patient gets the right test and the right prescription. Today, the hc1 Platform powers solutions that optimize diagnostic testing and prescribing for millions of patients nationally. To learn more about hc1’s proven approach to personalizing care while eliminating waste for thousands of health systems, diagnostic laboratories, and health plans, visit http://www.hc1.com and follow us on Twitter, Facebook, and LinkedIn.

Share article on social media or email:

ROCKVILLE, Md. (PRWEB)
April 23, 2020

SECO, a leading company in the hi-tech sector, specializing in computer miniaturization, backed by FII Tech Growth managed by Fondo Italiano d’Investimento SGR, today announced a partnership with IBD, an innovative Italian company operating in the biomedical market, for the development of Respira, a new non-invasive pulmonary ventilator created in response to the current health emergency of the COVID-19 pandemic. Respira was developed by a team of Italian doctors with direct and extensive experience on the front lines of the pandemic.

SECO’s technological capabilities in combination with IBD’s knowledge and competencies in the medical sector, have brought Respira to life. Respira is a compact and portable high-flux, pulmonary ventilator for patients with COVID-19-related pneumonia in both domestic and hospital environments. The new ventilators, which bypass the need for invasive intubation, are equipped with touchscreen displays for easy and intuitive use.

“It gives me great pride that in such difficult times two Italian industry leaders like SECO and IBD have brought together their technological competencies to provide a tangible contribution to the healthcare system and its patients, through an innovative, non-invasive and portable solution for pulmonary ventilation,” said Massimo Mauri, Chief Executive Officer for SECO.

Established in 2014, IBD designs and develops biomedical devices with the goal of innovating on portability, user-friendliness for healthcare personnel and patients, for both domestic and hospital applications. Following the concepts of “Less is More” and Lean Startup, IBD has developed, in a timely fashion and with limited resources, extremely innovative biomedical devices,” said Dr. Corrado Ghidini, MD of IBD. “As Italy has always been a leader in the biomedical field, the partnership with SECO provides the perfect complement for the realization of an industrial plan that can contribute in relaunching Italy on a global scale.”

In addition to ventilating patients affected by COVID-19 without intubation, Respira can also be used in immunodepression cases as well as those that require oxygenation in both pre-and post-intensive care. Designed in Italy and manufactured in the USA, the new pulmonary ventilators are expected to start deliveries between late May and early June 2020.

Assisted pulmonary ventilation is considered by most to be the only effective therapy for those patients affected by COVID-19-related respiratory deficiency. The innovative ventilators developed by SECO and IBD will contribute in increasing the availability of these fundamental medical devices, currently only available in limited amounts, at very high prices and exclusively used by intubated patients in ICUs.

About SECO

SECO is an Italian group with a leading global position in the sector of embedded technology and Internet of Things (IoT). Since 1979, it has been designing and producing embedded systems – industrial computers that are integrated into a client’s machine or tool, activating its functions and permitting interaction through touch/video interfaces. SECO collaborates with a broad network of strategic suppliers in the international high-tech panorama (including Intel®, AMD, NXP, NVIDIA®, Wind, and Telenor), as well as with universities, research centers and innovative start-ups, and operates on a global scale with offices in Italy, Germany, the U.S., India and Taiwan, employing more than 380 people. The industrial sectors in which SECO products are utilized range from biomedicine to wellness, industrial automation to transportation, and it has clients that are market leaders, such as Cimbali, Esaote, Evoca, and Technogym. http://www.seco.com

About FII Tech Growth

FII Tech Growth, with a fundraising target of €150 million, is the first Italian late-stage technology investment equity fund. It is managed by Fondo Italiano d’Investimento SGR and is dedicated to invest in the growth of small and medium-sized Italian companies with high-tech business models. The fund announced its first closing in September 2017 with Cassa Depositi e Prestiti as cornerstone investor. Fondo Italiano d’Investimento SGR currently manages a total of eight investment funds, dedicated to institutional investors, for a total of about Euro 3 billion of Assets Under Management. http://www.fondoitaliano.it

IBD

IBD is a biomedical devices manufacturer company conceived in London and founded in Italy in 2014. Guided by a team with +10 years of experience in dialysis and medical device design, IBD has raised so far over € 1 million in funding by angel investors and grants. It is now facing a new round of funding. http://www.ibdbiomed.com

Share article on social media or email:

Society for Immunotherapy of Cancer

“The contributions Drs. Chen, Freeman and Sharpe have made to the area of immune checkpoint inhibitors have fundamentally changed the treatment of cancer,” said SITC President Mario Sznol, MD.

MILWAUKEE (PRWEB)
April 23, 2020

The Society for Immunotherapy of Cancer (SITC) is pleased to announce Lieping Chen, MD, PhD, from Yale Cancer Center, Gordon Freeman, PhD, from the Dana-Farber Cancer Institute, and Arlene Sharpe, MD, PhD, from Harvard Medical School, as the 2020 recipients of the Richard V. Smalley, MD, Memorial Award and Lectureship, the society’s highest honor.

The research conducted by Drs. Chen, Freeman and Sharpe formed the foundation for developing immune checkpoint blockade immunotherapies and will be featured during the society’s 35th Anniversary Annual Meeting in November at the Gaylord National Hotel & Convention Center in National Harbor, Md.

“The contributions Drs. Chen, Freeman and Sharpe have made to the area of immune checkpoint inhibitors have fundamentally changed the treatment of cancer,” said SITC President Mario Sznol, MD. “The current success of cancer immunotherapy can be traced back to their foundational mechanistic studies and commitment to translating their findings to the clinic.”

Dr. Chen’s lab studied lymphocyte costimulation and coinhibition and their application in treating human diseases for over 25 years. In 1992, his lab published the first proof-of-concept study showing that manipulation of B7-CD28 family molecules could be used for cancer immunotherapy by introducing B7-1 into tumor cells to enhance tumor immunity.

This study led to additional studies utilizing antibodies targeting CTLA-4, a B7-CD28 family molecule, for the treatment of human cancer. From 1999–2002, Dr. Chen’s lab cloned the B7-H1 (PD-L1) molecule and discovered the PD-1/PD-L1 pathway’s role in the evasion of tumor immunity and established this pathway as a target for cancer immunotherapy.

Dr. Chen will deliver his Richard V. Smalley, MD, Memorial Lectureship, “Why were we interested in immunity within the tumor microenvironment in the 1990s?” at SITC 2020. He explained, “Early in our research, less attention was paid to our work. But then, the most exciting thing we found was that the PD-1/PD-L1 pathway play a key role in cancer escape from immune attack, which led us to investigate further to help development of anti-PD-1/PD-L1 therapy.”

Dr. Chen is the United Technologies Corporation Professor in Cancer Research, Professor of Immunobiology, Dermatology and Medical Oncology at Yale School of Medicine, and co-leader of the Cancer Immunology Program at the Yale Cancer Center. Dr. Chen earned his medical degree from Fujian Medical School and earned his doctorate from Drexel University School of Medicine.

The research conducted by Dr. Freeman’s lab identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28). His group’s discovery of PD-L1 and PD-L2 demonstrated that these molecules were ligands for PD-1, thereby defining the PD-1 pathway and the potential of drugs to block these interactions. Dr. Freeman demonstrated that PD-L1 is highly expressed on many solid tumors as well as some hematologic malignancies, which allows these tumors to inhibit immune responses. He made antibodies that blocked the PD-1 pathway and showed they enhanced immune responses.

“The PD-L1/PD-1 Pathway: Discovery and New Insights,” is the title of Dr. Freeman’s Richard V. Smalley, MD, Memorial Lectureship. “This success of PD-L1 and PD-1 immunotherapy has given patients new hope and energized scientists and drug developers as never before. We are finding what works, what’s safest, how it works, and who it will work for,” said Dr. Freeman when describing the impact of his work.

Dr. Freeman is in the Department of Medical Oncology at Dana-Farber Cancer Institute and is a Professor of Medicine at Harvard Medical School. Dr. Freeman earned his bachelor’s degree in biochemistry and molecular biology, and doctorate in microbiology and molecular genetics from Harvard University. Dr. Freeman is a Fellow of the AACR Academy and the recipient of the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology and the 2017 recipient of the Warren Alpert Foundation award.

Dr. Sharpe has used genetic approaches to discover T cell costimulatory molecules and understand their functions. Her studies with B7 (CD80) deficient mice led to the discovery of B7-2 (CD86) and the realization that it was the major CD28 ligand. Her work on CTLA-4 knockout mice convinced the field that CTLA-4 was a critical inhibitory molecule and a key mediator of T cell tolerance. Her studies of PD-1 and its ligand revealed that the inhibitory functions of this pathway control resolution of inflammation and tolerance in tissues.

Recently, her laboratory has developed a CRISPR/Cas9 screening platform to identify genes that regulate T cell tolerance and T cell exhaustion in immune cells, and is using this approach to determine how perturbation of coinhibitory receptors and other immunoregulatory genes can improve responses to PD-1 checkpoint blockade. Dr. Sharpe will deliver her Richard V. Smalley, MD, Memorial Lectureship titled, “Discovery of New IO Targets and Mechanisms Leveraging CRISPR” discussing her recent work. “The PD-1 story emphasizes the value of discovery and curiosity-driven research,” she says. “This work did not start out to understand how to cure cancer. We were studying how the immune system was regulated, and discovered a key mechanism tumors use to evade immune attack.”

Dr. Sharpe is the George Fabyan Professor of Comparative Pathology, Chair of the Department of Immunology at Harvard Medical School, and Co-Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. She is a member of the Department of Pathology at Brigham and Women’s Hospital, a Member of the Broad Institute of MIT and Harvard, Leader of the Cancer Immunology Program at the Dana-Farber/Harvard Cancer Center. Dr. Sharpe earned her medical degree and doctorate from Harvard Medical School and completed her residency in pathology at Brigham and Women’s Hospital. She is a member of the National Academy of Sciences and the National Academy of Medicine. Dr. Sharpe is the 2014 recipient of the William B. Coley Award for Distinguished Research in Tumor Immunology, the 2017 recipient of the Warren Alpert Foundation Prize for her contributions to the discovery of the PD-1 pathway, and a fellow of the AACR.

The Smalley Memorial Award, established by SITC in 2005 and awarded annually to a clinician or scientist who has significantly contributed to the advancement of research in the field of cancer immunotherapy, is named in honor of the past SITC president and charter member of the society.

Previous recipients of the Smalley Award are: Olivera J. Finn, PhD; Philip D. Greenberg, MD; Paul M. Sondel, MD, PhD; Suzanne L. Topalian, MD; Tasuku Honjo, MD, PhD; Giorgio Trinchieri, MD; Carl H. June, MD; Theresa L. Whiteside, PhD; Ralph M. Steinman, MD; James P. Allison, PhD; Isaiah J. Fidler; DVM, PhD; Giorgio Parmiani, MD; Ernest Borden, MD; Ronald Levy, MD, and Steven A. Rosenberg, MD, PhD.

To learn more about this award, visit SITC CONNECT. Registration is now underway for the 35th Anniversary Annual Meeting (SITC 2020), click here to register, submit research, view sessions and more.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.